Title
Pharmacological aspects of neuro-immune interactions
Date Issued
01 January 2018
Access level
metadata only access
Resource Type
editorial
Author(s)
Pontificia Universidad Javeriana
Publisher(s)
Bentham Science Publishers B.V.
Abstract
The use of systematic approach for the analysis of mechanism of action of drugs at different levels of biological organization of organisms is an important task in experimental and clinical pharmacology for drug designing and increasing the efficacy and safety of drugs. The analysis of published data on pharmacological effects of psychotropic drugs possessing immunomodulatory and/or antiviral properties have shown a correlation between central effects of examined drugs associated with the impact on the processes of neurogenesis of adult brain and survival of neurons, and their ability to alter levels of key proinflammatory cytokines. The changes that occur as a result of the influence of pharmacological agents at one of the systems should inevitably lead to the functional reorganization at another. Integrative mechanisms underlying the neuro-immune interactions may explain the "pleiotropic" pharmacological effects of some antiviral and immunomodulatory drugs. Amantadine, which was originally considered as an antiviral agent, was approved as anti-parkinsonic drug after its wide medical use. The prolonged administration of interferon alpha caused depression in 30-45% of patients, thus limiting its clinical use. The antiviral drug “Oseltamivir” may provoke the development of central side effects, including abnormal behavior, delirium, impaired perception and suicides. Anti-herpethetical drug “Panavir” shows pronounced neuroprotective properties. The purpose of this review is to analyze the experimental and clinical data related to central effects of drugs with antiviral or/and immunotropic activity, and to discover the relationship of these effects with changes in reactivity of immune system and proinflammatory response.
Start page
15
End page
21
Volume
24
Issue
1
Language
English
OCDE Knowledge area
Farmacología, Farmacia
Subjects
Scopus EID
2-s2.0-85045980855
PubMed ID
Source
Current Pharmaceutical Design
ISSN of the container
13816128
Source funding
Russian Science Foundation
Sponsor(s)
This work supported by the Russian Scientific Foundation ((www.rscf.ru, Российский Научный Фонд, Grant №14-23 00160P: Directed design, synthesis, and study of biological activity of multi-target compounds as innovative drugs for treatment of neurodegenerative diseases). GEB work is supported by Pontificia Universidad Javeriana. GMA gratefully acknowledges the facilities provided by King Fahad Medical Research Center (KFMRC), King Abdulaziz University, Jeddah, Saudi Arabia.
Sources of information:
Directorio de Producción Científica
Scopus